Table 1.
Baseline characteristics
| No. of patients | Percent | |
|---|---|---|
| All patients | 653 | 100 |
| Age at inclusion | ||
| ≥ 55 years | 271 | 41.5 |
| < 55 years | 382 | 58.5 |
| T status | ||
| pT1 | 377 | 57.8 |
| pT2 | 234 | 35.8 |
| pT3-4 | 26 | 4.0 |
| pTX | 16 | 2.5 |
| N status | ||
| pN0 | 419 | 64.2 |
| pN1 | 136 | 20.8 |
| pN2 | 59 | 9.0 |
| pN3 | 23 | 3.5 |
| pNX | 16 | 2.5 |
| Histological grade | ||
| I | 153 | 23.4 |
| II | 322 | 49.3 |
| III | 177 | 27.1 |
| Missing | 1 | 0.2 |
| HR status | ||
| Positive (≥ 10%) | 512 | 78.4 |
| Negative (0 to < 10%) | 137 | 21.0 |
| Missing | 4 | 0.6 |
| HER2 status | ||
| Negative | 578 | 88.5 |
| Positive | 71 | 10.9 |
| Missing | 4 | 0.6 |
| HR/HER2 subclasses | ||
| HR+/HER2− | 476 | 72.9 |
| HR+/HER2+ | 36 | 5.5 |
| HR−/HER2+ | 35 | 5.4 |
| HR−/HER2− | 102 | 15.6 |
| Missing | 4 | 0.6 |
| Ki-67 (n = 218)a | ||
| < 15% | 103 | 47.2 |
| 15–30% | 77 | 35.3 |
| ≥ 30% | 38 | 17.4 |
| Histological subtype | ||
| Ductal | 499 | 76.4 |
| Lobular | 121 | 18.5 |
| Other | 33 | 5.1 |
| Adjuvant treatment | ||
| No adjuvant | 331 | 50.7 |
| Tamoxifen only | 164 | 25.1 |
| CMF with or without Tam | 158 | 24.2 |
Abbreviations: CMF Cyclophosphamide, methotrexate, fluorouracil, HER2 Human epidermal growth factor receptor 2, HR Hormone receptor, TAM Tamoxifen
aKi-67 analysis (hot spot) of the pT1pN0 patients, 171 of whom were HR+/HER2−